Efficacy of Tarlatamab in limited-stage small cell lung cancer

As of2025, tarlatamab (Tarlatamab, brand name Imdelltra) is mainly used to treat extensive-stage small cell lung cancer (ES-SCLC) and has not been approved in limited-stage small cell lung cancer (LS-SCLC). Currently, the efficacy of talatumumab in LS-SCLC is still in the clinical research stage, and there is no complete clinical data to support its application in this indication.

Currently, the efficacy of talatumumab inLS-SCLC has not been fully verified. However, there are studies evaluating its potential in this indication. For example, the DeLLphi-306 trial (NCT06117774) is ongoing to evaluate the efficacy and safety of talatumumab in patients with LS-SCLC. The preliminary results of this study may provide more basis for the application of talatumumab in LS-SCLC.

Talatuzumab is a bispecific T cell engaging agent that simultaneously binds to DLL3 protein and on the surface of tumor cells. The CD3 receptor on the surface of pan>T cells promotes T cells to recognize and kill tumor cells. Talatumumab has shown some anti-tumor activity in ES-SCLC patients. However, the tumor biological characteristics of LS-SCLC patients may be different from ES-SCLC, which may affect the efficacy of talatumumab in LS-SCLC.

In conclusion, the efficacy of talatumumab inLS-SCLC has not been fully verified. Currently, relevant clinical research is ongoing, which may provide more basis for its application in this indication in the future. Patients should discuss the potential benefits and risks of treatment with their doctor before receiving treatment.

Reference materials:https://www.drugs.com